ImmuPharma

ImmuPharma Focuses on Developing Novel Peptide Biopharmaceuticals.ImmuPharma closely collaborates with the French National Centre for Scientific Research (CNRS), the largest fundamental research institution in Europe. This collaboration enables ImmuPharma to achieve significant research outcomes and work with numerous scientists and doctors.ImmuPharma’s achievements primarily target four product areas: autoimmune diseases, anti-infectives, metabolism, and cancer.Research and development outcomes include:Lupuzor™ (P140) for lupus (Ph 2/3 adaptive/pivotal);P140 for CIDP (Ph 2/3 adaptive/pivotal);BioAMB, a novel improved version of Amphotericin B (late preclinical);BioCIN, a novel improved version of Vancomycin (early preclinical).